

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



偉俊生物科技有限公司

Wai Chun Bio-Technology Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 660)

PROFIT ALERT – SUBSTANTIAL REDUCTION IN LOSS

This announcement is made by Wai Chun Bio-Technology Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors of the Company (the “**Board**”) wishes to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that, based on a preliminary assessment of the unaudited consolidated management accounts of the Group for the six months ended 31 December 2025, the Group is expected to record a net loss of the Group of not more than HK\$6.0 million for the six months ended 31 December 2025, representing a substantial reduction in loss as compared with the net loss of the Group of approximately HK\$13.1 million for the six months ended 31 December 2024. The substantial reduction in loss was primarily attributable to the increase in revenue and decrease in finance costs during the reporting period.

The Company is still in the process of finalising the interim results of the Group for the six months ended 31 December 2025. The information contained in this announcement is only based on the Board’s preliminary assessment of the unaudited consolidated management accounts of the Group for the six months ended 31 December 2025, which have not been reviewed by the audit committee of the Company. The interim results of the Group for the six months ended 31 December 2025 will be published by the Company within the timeframe stipulated under the Listing Rules.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Wai Chun Bio-Technology Limited
Lam Ka Chun
Chairman

Hong Kong, 25 February 2026

As at the date of this announcement, the Board comprises:

Executive Director:

Mr. Lam Ka Chun (*Chairman and Chief Executive Officer*)

Independent Non-executive Directors:

Mr. Wong Po Keung

Mr. Wang Ziniu

Ms. Xu Huiling